Journal
OPEN FORUM INFECTIOUS DISEASES
Volume 4, Issue 3, Pages -Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofx147
Keywords
clofazimine; Mycobacterium abscessus; nontuberculous mycobacteria; rapidly growing mycobacteria
Categories
Funding
- University of Washington Internal Medicine Residency Training Program
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007044] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Infection secondary to rapidly growing mycobacteria (RGM) is associated with significant morbidity and mortality, especially in individuals with underlying structural lung disease or immune compromise. Such infections, particularly those caused by the Mycobacterium abscessus group, are challenging to treat due to high virulence, antibiotic resistance, and the lack of effective and tolerable therapies. Although novel antimycobacterials are under development, clofazimine-a drug historically administered as part of multidrug therapy regimens for Mycobacterium leprae-holds promise as a chemotherapeutic for the treatment of RGM. The history, pharmacologic properties of clofazimine, as well as in vitro and in vivo studies against RGM are described here and highlight a potential new niche for an old drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available